DE69429816D1 - C1-Esterasehemmer zur Verringerung von Myokardschäden bei akutem Herzinfarkt - Google Patents

C1-Esterasehemmer zur Verringerung von Myokardschäden bei akutem Herzinfarkt

Info

Publication number
DE69429816D1
DE69429816D1 DE69429816T DE69429816T DE69429816D1 DE 69429816 D1 DE69429816 D1 DE 69429816D1 DE 69429816 T DE69429816 T DE 69429816T DE 69429816 T DE69429816 T DE 69429816T DE 69429816 D1 DE69429816 D1 DE 69429816D1
Authority
DE
Germany
Prior art keywords
esterase inhibitor
myocardial infarction
acute myocardial
pct
recombinant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69429816T
Other languages
English (en)
Other versions
DE69429816T2 (de
Inventor
Theodoor Hermens
Erik Hack
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stichting Sanquin Bloedvoorziening
Original Assignee
Stichting Sanquin Bloedvoorziening
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stichting Sanquin Bloedvoorziening filed Critical Stichting Sanquin Bloedvoorziening
Publication of DE69429816D1 publication Critical patent/DE69429816D1/de
Application granted granted Critical
Publication of DE69429816T2 publication Critical patent/DE69429816T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Electrotherapy Devices (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69429816T 1993-09-01 1994-08-31 C1-Esterasehemmer zur Verringerung von Myokardschäden bei akutem Herzinfarkt Expired - Lifetime DE69429816T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP93202572 1993-09-01
PCT/NL1994/000208 WO1995006479A1 (en) 1993-09-01 1994-08-31 Method to reduce myocardial injury during acute myocardial infarction

Publications (2)

Publication Number Publication Date
DE69429816D1 true DE69429816D1 (de) 2002-03-21
DE69429816T2 DE69429816T2 (de) 2002-09-19

Family

ID=8214075

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69429816T Expired - Lifetime DE69429816T2 (de) 1993-09-01 1994-08-31 C1-Esterasehemmer zur Verringerung von Myokardschäden bei akutem Herzinfarkt

Country Status (10)

Country Link
US (1) US6090777A (de)
EP (1) EP0716611B1 (de)
JP (2) JP4077030B2 (de)
AT (1) ATE212859T1 (de)
AU (1) AU678064B2 (de)
DE (1) DE69429816T2 (de)
DK (1) DK0716611T3 (de)
ES (1) ES2171465T3 (de)
PT (1) PT716611E (de)
WO (1) WO1995006479A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19829014A1 (de) * 1998-06-30 2000-01-05 Centeon Pharma Gmbh Modifizierter C1-Esterase-Inhibitor zur Blockierung der Infektiosität von HIV
US7008645B2 (en) * 1998-07-14 2006-03-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method of inhibiting restenosis using bisphosphonates
CA2426115A1 (en) * 2003-04-18 2004-10-18 Victor Gurewich Methods, devices, and compositions for lysis of occlusive blood clots while sparing wound sealing clots
US10517883B2 (en) 2003-06-27 2019-12-31 Zuli Holdings Ltd. Method of treating acute myocardial infarction
US20060051407A1 (en) * 2003-06-27 2006-03-09 Yoram Richter Method of treating ischemia-reperfusion injury
US20070196367A1 (en) * 2006-02-22 2007-08-23 Valentin Dinu Methods of preventing and treating Alzheimer's disease, age related macular degeneration and other diseases involving extra-cellular debris through the inhibition of the complement system
US20090010916A1 (en) * 2006-06-22 2009-01-08 Victor Gurewich C-1 Inhibitor prevents non-specific plasminogen activation by a prourokinase mutant without impeding fibrin-specific fibrinolysis
PL3028716T3 (pl) 2006-10-10 2021-03-08 Regenesance B.V. Hamowanie układu dopełniacza służące do lepszej regeneracji nerwów
CN104870475B (zh) 2012-10-25 2019-11-08 美国比奥维拉迪维股份有限公司 抗补体C1s抗体和其用途
CA2889197A1 (en) 2012-11-02 2014-05-08 True North Therapeutics, Inc. Anti-complement c1s antibodies and uses thereof
DK2961422T3 (en) * 2013-02-28 2017-01-16 Csl Behring Gmbh Therapeutic agent for amniotic fluid embolism
US10286047B2 (en) * 2013-03-08 2019-05-14 Csl Behring Gmbh Treatment and prevention of remote ischemia-reperfusion injury
US9993427B2 (en) 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture
EP2968434B1 (de) 2013-03-15 2017-06-28 Shire Viropharma Incorporated C1-inh-zusammensetzungen zur vorbeugung und behandlung von herditärem angioödem
KR20160026905A (ko) * 2013-06-28 2016-03-09 체에스엘 베링 게엠베하 인자 ｘｉｉ 억제제 및 ｃ1-억제제를 이용한 병용 치료요법
PT3280440T (pt) 2015-04-06 2023-02-14 Bioverativ Usa Inc Anticorpos anti-c1s humanizados e métodos de utilização destes

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3228502A1 (de) * 1982-07-30 1984-02-02 Behringwerke Ag, 3550 Marburg Verfahren zur herstellung des c1-inaktivators und seine verwendung
FR2601034B1 (fr) * 1986-07-03 1989-11-17 Pasteur Institut Inhibiteur de l'activite de la c1-esterase plasmatique (c1-inhibiteur) et d'autres enzymes proteolytiques du groupe des proteases a serine, son procede de preparation, acides nucleiques codant pour cet inhibiteur, methodes de detection d'affections correlees aux defauts dudit inhibiteur a l'aide d'anticorps ou de sondes nucleotidiques et medicaments contenant ledit inhibiteur de synthese
CA2071871A1 (en) * 1989-10-27 1991-04-28 Eric Eldering C1 inhibitor muteins and uses thereof
WO1992022320A1 (en) * 1991-06-14 1992-12-23 Genentech, Inc. C1 inhibitor variants and treating inflammatory response with c1 inhibitor

Also Published As

Publication number Publication date
AU7823994A (en) 1995-03-22
DK0716611T3 (da) 2002-05-21
EP0716611B1 (de) 2002-02-06
EP0716611A1 (de) 1996-06-19
US6090777A (en) 2000-07-18
WO1995006479A1 (en) 1995-03-09
JP2008056705A (ja) 2008-03-13
ES2171465T3 (es) 2002-09-16
JP4077030B2 (ja) 2008-04-16
JPH09501946A (ja) 1997-02-25
AU678064B2 (en) 1997-05-15
PT716611E (pt) 2002-06-28
ATE212859T1 (de) 2002-02-15
DE69429816T2 (de) 2002-09-19

Similar Documents

Publication Publication Date Title
DE69429816D1 (de) C1-Esterasehemmer zur Verringerung von Myokardschäden bei akutem Herzinfarkt
BR9908280A (pt) Inibidores de enzimas de fosfolipase
MY129998A (en) Saccharin derivative proteolytic enzyme inhibitors
MX9700237A (es) Combinaciones inhibidoras de proteasa retroviral.
MY129293A (en) The use of mmp-13 selective inhibitors for the treatment of osteoarthristis and other mmp-mediated disorders
EP0374440A3 (de) Hemmer der Lysyl-Oxydase
DK0966465T3 (da) Inhibitorer af IMPDH-enzymer
MY131388A (en) Inhibitors of hiv protease useful for the treatment of aids.
MD1507G2 (ro) Inhibitori, compoziţie farmaceutică pe baza lor şi procedeu de inhibare a HIV proteazei
HU9204029D0 (en) Proteolytic enzym inhibitors
AU7321598A (en) Use of cholinesterase inhibitors to treat disorders of attention
DE69410254D1 (de) Behandlung von mycobakteriellen erkrankungen durch verabreichung von bakrerientötende, durchlässigkeitserhöhende proteinfragmente
ZA962592B (en) Transdermally administrable medicament with ace inhibitors.
DK0662948T3 (da) 2-amino-4-phenyl-4-oxosmørsyrederivater med kynureninase- og/eller kynurenin-3-hydroxylaseinhiberende virkning
ATE277943T1 (de) Trypsininhibitoren
MX9305784A (es) N-(aceilaminometil) glutaril amino acidos.
AU7934900A (en) Method of screening for inhibitors of asp2
PL327818A1 (en) Novel medical application of ace inhibitor in treating dipeptic symptoms
DE69333953D1 (de) Promotor des transaldolase-genes von k.lactis und dessen verwendung
AU8811298A (en) Novel peptides and polypeptides useful for regenerating the nervous system
CZ157795A3 (en) Pharmaceutical preparations for treating prostatitis
CA2170739A1 (en) Method to reduce myocardial injury during acute myocardial infarction
ATE184287T1 (de) Derivate von therapeutisch in der blutgerinnungskaskade wirksamen peptiden, verfahren zur herstellung und sie enthaltende pharmazeutische zubereitungen
DE60006284D1 (de) Arzneimittel zur behandlung konvulsivischer zustände
AU4390597A (en) Combination therapy for treatment of arthritic diseases

Legal Events

Date Code Title Description
8364 No opposition during term of opposition